Alnylam Pharmaceuticals, Inc. vs Global E Online Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.88 (market cap $29.60B), while Global E Online Ltd trades at $42 (market cap $6.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.3× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GLBE | |
|---|---|---|
Market Cap | $29.60B | $6.87B |
Sector | Health | Technology |
52-Week High | $491.22 | $42.32 |
52-Week Low | $205.48 | $27.54 |
Enterprise Value | $27.56B | $6.34B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
GLBE trades at $42.08, up 2.26% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS expectations and raising full-year guidance, driven by 39% revenue growth and expanded EBITDA margins. Analyst consensus is unanimously bullish with a $44.75 price target, reflecting confidence in its e-commerce enablement platform.
The stock offers upside potential from robust growth and strategic acquisitions like Passport, but risks include high valuation multiples (P/E of 61.06) and insider selling. Execution on raised guidance and integration of new logistics capabilities are key to sustaining momentum amid competitive pressures.
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →